Indeed, previous work from our group has shown that a prolonged treatment with the GLP1- agonist Exendin-4 [49] and the DPP-4 inhibitor Linagliptin [50] initiated after stroke, improved stroke recovery in association with normalized glucose metabolism. The gene discussed is GLP1R; the disease is Stroke.